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Summary We analysed data from a case-control investigation conducted in Milan, Northern Italy, to
evaluate the relation between the use of combination oral contraceptives and the risk of cancers of the breast,
ovary, endometrium and cervix uteri. For the present analysis, 776 cases of histologically confirmed breast
cancer, 406 of epithelial overian cancer and 170 of endometrial cancer aged under 60 were compared with a
group of 1,282 subjects below age 60 admitted for a spectrum of acute conditions apparently unrelated to oral
contraceptive use or to any of the known or potential risk factors for the diseases under study. Likewise, 225
cases of invasive cervical cancer were compared with 225 age-matched inpatient controls, and 202 cases of
cervical intra-epithelial neoplasia with 202 outpatient controls identified in the same screening clinics. The
age-adjusted relative risk estimates for ever vs. never use of combination oral contraceptives were 1.04 (95%
confidence interval (CI) 0.73-1.37) for breast cancer, 0.68 (95% CI=0.48-0.97) for epithelial ovarian cancer,
0.50 (95% CI=0.23-1.12) for endometrial cancer, 1.49 (95% CI=0.88-2.55) for cervical cancer and 0.77
(95% CI=0.50-1.18) for cervical intra-epithelial neoplasia. The risk of ovarian cancer decreased and that of
invasive cervical cancer increased with longer duration of use. Neither duration of oral contraceptive use nor
time since first or last use significantly altered a user's risk of other neoplasms considered. Likewise, analysis
of sub-groups of age, parity or other potentially important covariates did not show any important interaction,
and allowance for them by means of logistic regression did not materially modify any of the results. These
data confirm that combination oral contraceptives confer some protection against ovarian and endometrial
cancers but may increase the risk of invasive cervical cancer if used for several years, and indicate that the
past or current pattern of oral contraceptive use in Italy is unlikely materially to affect the risk of breast
cancer.
Several studies have been published on the relation
between oral contraceptives (OC) and cancers of
the breast and of the female genital tract, mostly
conducted in North America or Britain. In general,
they give suggestive evidence that oral contracep-
tives may confer protection against cancers of the
endometrium (Kaufman et al., 1980; Centers for
Disease Control Cancer and Steroid Hormone
Study, 1983c) and of the ovary (Centers for Disease
Control Cancer and Steroid Hormone Study,
1983b; Newhouse et al., 1977; Rosenberg et al.,
1982; Weiss et al., 1981). The risk of cervical cancer
for oral contraceptive users, on the other hand, was
elevated in several studies (Harris et al., 1980; Kay,
1983; Vessey et al., 1983b; WHO Collaborative
Study of Neoplasia and Steroid Contraceptives,
1985): the overall estimate of the increased risk,
however, was relatively limited, and it is difficult in
such a situation to distinguish between a causal
association and a confounding effect potentially
due to differences in sexual habits (Franceschi et
al., 1986). With regard to breast cancer, various
studies have shown elevated risks in subgroups with
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positive family history of breast cancer (Brinton et
al., 1982), previous breast biopsy for benign
conditions (Brinton et al., 1982; Fasal &
Paffenbarger, 1975; Janerich et al., 1983) in women
who had used oral contraceptives before birth of
the first child (Pike et al., 1981), or in young long-
term users of oral contraceptives (Pike et al., 1983;
McPherson et al., 1983). These results, however,
were often not confirmed by subsequent studies and
there is at present little convincing evidence of any
association between oral contraceptive use and
breast cancer risk (Centers for Disease Control
Cancer and Steroid Hormone Study, 1983a;
Rosenberg et al., 1984; Vessey et al., 1983a;
Hennekens et al., 1984; Stadel et al., 1985; Lipnick
et al., 1986).
In view of these uncertainties, and of the large
public health importance of the issue, it may be of
interest to consider the risk estimates for oral
contraceptive use in further sets of data from
different populations. In the present paper, we have
summarized the interim results from a case-control
study of cancers of the breast and of the female
genital tract conducted in northern Italy. The data
on ovanan cancer only have been partly published
in a separate paper (La Vecchia et al., 1984a).
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Subjects and methods
Since 1979, we have conducted a case-control study
of neoplasms of the female genital tract (ovary,
endometrium and cervix); recruitment of breast
cancer cases started in 1982. The design of this
study has already been described (La Vecchia et al.,
1984a, b, c). Briefly, trained interviewers identify
and question women admitted for the neoplasms
under study and for a wide spectrum of other
conditions to University and General Hospitals in
the greater Milan area. On average, less than 2 per
cent of the eligible women (cases or controls) refuse
to be interviewed.
A standard questionnaire is used to obtain
information on personal characteristics and habits,
gynaecological and obstetric data, related medical
history and history of lifetime use of oral
contraceptives and other female hormones. The
time and duration of use are recorded, as well as
the brand name. Photographs of packages of the
most common brands are provided to assist recall,
whenever useful. The same questionnaire is used for
cases of breast, ovarian and endometrial cancer,
and their controls. For cases of cervical neoplasia
and related controls, a detailed history of sexual
habits and other variables of potential importance
(e.g. history of cervical screening) is also elicited.
The present paper is based on data obtained before
November 30, 1985.
Cases
The cases studied were women with histologically
confirmed cancers of the breast, ovary (epithelial
only), endometrium and cervix (invasive) diagnosed
within the year prior to inter-view, admitted to the
National Cancer Institute, the Ospedale Maggiore
of Milan (including the four largest teaching
hospitals in Milan) and to the Obstetrics and
Gynaecology Clinics of the University of Milan.
There were 776 breast cancer cases younger than 60
years who met these criteria, 406 ovarian cancers,
170 endometrial cancers and 225 cervical cancers.
Furthermore, 202 outpatients with histologically
confirmed cervical intraepithelial neoplasia were
identified in the cervical screening services of the
First Obstetrics and Gynaecology Clinic of the
University of Milan. Among them, 44 (22%) were
classed histologically as CIN I, 51 (25%) CIN II,
and 107 (53%) CIN III.
Controls
The criteria of selection of controls were the same
for all invasive cancers, but not for the comparison
group of cervical intraepithelial neoplasia. Potential
controls for invasive cancers were all women below
the age of 60 years whose primary diagnosis was of
acute conditions judged to be unrelated to any of
the established or suspected risk factors for breast
or female genital tract neoplasms, admitted to the
same network of hospitals where cases had been
identified (chiefly the Ospedale Maggiore of Milan
and a few other specialized University Clinics, such
as orthopaedics, eye, ENT, etc.). Women were not
eligible if they were admitted for gynaecological,
hormonal or neoplastic diseases, or had undergone
bilateral oophorectomy or hysterectomy.
The major control group (1,282 patients) was
compared in turn with cases of breast, ovarian and
endometrial cancer. On account of the different age
distributions of the three case series and of the
control group, age (in decades) was allowed for all
analysis purposes. Of these control subjects, 33%
had been admitted because of traumatic conditions,
24% for non-traumatic orthopaedic disorders
(mostly low back pain and disc disorders), 15% for
surgical conditions (mostly abdominal, such as
acute appendicitis or strangulated hernia), and 28%
for other illnesses such as eye, ear, nose and throat,
and teeth disorders.
Controls for invasive cervical cancer, whose
information was collected on a modified question-
naire (see above) were individually matched with
cases for age in decades. Among them (225
patients), 28% had traumatic conditions, 30% were
admitted for non-traumatic orthopaedic disorders,
21% for acute surgical diseases, and 21% for other
conditions (eye. ENT, etc.).
The control group for subjects with CIN
consisted of women (n=202) found to have normal
cervical smears at the same screening clinics where
CIN subjects had been identified. They were also
matched with cases for age in decades.
Data analysis and control ofconfounding
We computed the odds ratios (as estimators of the
relative risks), together with their 95% approximate
confidence intervals (CI) of various cancers among
women who had used combination oral contracep-
tives relative to women who had never used them
(Breslow & Day, 1980). Tests for linear trend in
risk, where appropriate, were done by the method
given by Mantel (1963).
Decade of age was allowed for in all analyses
by the Mantel-Haenszel procedure (Mantel &
Haenszel, 1959). Likewise, other potentially
confounding variables, including the major risk
factors for the diseases studied, determinants of
contraceptive use or other covariates of potential
interest such as cigarette smoking or non-
contraceptive oestrogen use were examined and
controlled for individually, using the Mantel-
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those variables, however, had only limited effects
on the relative risk estimates, and is therefore not
presented. Finally, all the identified potential
confounding factors were controlled simultaneously
by means of multiple logistic regression, fitted by
the method of maximum likelihood (Breslow &
Day, 1980). Included in the regression equations for
all neoplasms were terms for oral contraceptive use,
other contraceptive practices, age, marital status,
education and other indicators of social class,
parity, age at menarche, at first birth and at
menopause, body mass index, cigarette smoking,
noncontraceptive female hormone use and (for
cervical neoplasia only) number of sexual partners,
age at first intercourse, number of screening Pap
smears and time since last smear.
Results
The distribution of cases and controls according to
ever use, duration and time since first ('latency') or
last ('recency') use of oral contraceptives is given in
Table I. The corresponding risk estimates are
reported in Tables II (ever use), III (duration of
use) and IV (latency and recency). In Table V
separate relative risks are shown in various strata
of age or parity.
Cancer ofthe breast
Ever use of oral contraceptives was reported by 104
(13.4%) of the cases, giving an age adjusted relative
risk of 1.04 (95% CI=0.73-1.37). After allowance
Table I Distribution of cases of breast and female genital tract neoplasia and controls according to ever use, duration,
latency and recency of use of oral contraceptives (OC). Milan, Italy 1979-85
Breast Ovarian Endometrial Cervical Cervical
cancer cancer cancer Controls cancer Controls intraepithelial Controls
Variables (n = 776) (n=406) (n=170) (n=1,282) (n=225) (n=225) neoplasia (n=202) (n=202)
Oral contraceptive use
Never 672 367 163 1,104 182 193 131 120
Ever 104 39 7 178 43 32 71 82
Duration ofuse
(years)
.2 63 29 3 109 28 25 38 49
>2 41 10 4 69 15 7 33 33
Time sincefirst
OC use (years)
< 10 41 19 2 105 26 17 46 60
. 10 63 20 5 72 17 15 25 22
Unknown 1
Time since last
OC use (years)
<5 28 11 2 84 16 7 46 37
>5 76 27 5 93 27 25 25 45
Unknown 1 1
Table II Relative risk (RR) estimates of breast and female genital tract neoplasms in relation to ever use of oral
contraceptives (OC) (based on data in Table I)
Relative risk estimates (95% CI) in ever vs. never OC usersfor:
Cervical
Breast Ovarian Endometrial Cervical intraepithelial
cancer cancer cancer cancer neoplasia
M-H RRa 1.04 0.68 0.50 1.49 0.77
(0.73-1.37) (0.48-0.97) (0.23-1.12) (0.88-2.55) (0.50-1.18)
Multivariate RRb 1.13 0.65 0.56 1.74 0.69
(0.81-1.52) (0.42-0.96) (0.21-1.30) (0.85-3.57) (0.42-1.09)
aM-H indicates the Mantel-Haenszel estimates, adjusted for age in decades; bEstimates from multiple logistic regression.
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for all identified potential confounding factors by
means of multiple logistic regression, the estimate
was 1.13 (0.81-1.52, Table II).
There was no appreciable influence of duration
of use (Table III), whereas the point estimates
tended to be below unity for shorter latency or
recency intervals and, symmetrically, above unity
for longer intervals (Table IV). Finally, the point
estimates were not materially heterogeneous in
various strata of age (including women below age
40, where the relative risk was 0.87 with 95%
CI=0.56-1.36), or parity (Table V).
Cancer ofthe ovary
thirty nine (9.6%) women with epithelial ovarian
cancer had at one time used combination oral
contraceptives. The relative risk for ever versus
never use was 0.68 (95% CI=0.48-0.97) when only
age was allowed for and 0.65 (95% CI=0.42-0.96)
when allowance was made for all identified
potential confounding factors (Table II). The risk
of ovarian cancer decreased with increasing
duration of use, the point estimates declining to
0.52 for women who had used oral contraceptives
for more than two years. This trend in risk was
statistically significant (Table III).
The protection appeared to be long lasting, since
the risk estimates remained below unity several
years after first (RR=0.83 for 10 or more years) or
last (RR=0.75 for 5 or more years) OC use (Table
IV). Likewise, the decreased risk of ovarian cancer
Table III Relative risk estimates of breast and female genital tract neoplasms in relation to
duration of.oral contraceptive (OC) use (based on data in Table I)
Relative risk estimates (95% CI)ab
Cervical
Breast Ovarian Cervical intraepithelial
cancer cancer cancer neoplasia
Duration ofuse (years)
.2 1.02 0.81 1.26 0.68
(0.73-1.44) (0.54-1.25) (0.69-2.30) (0.41-1.13)
>2 1.07 0.52 2.94 0.88
(0.70-1.63) (0.29-0.96)c (1.107.84)d (0.64-2.02)
aMantel-Haenszel estimates, adjusted for age in decades. bReference category: never OC users.
CTest for trend x2=5.33; P =0.02. dTest for trend X2=4.42; P=0.04.
Table IV Relative risk estimates of breast and female genital tract neoplasms in relation to latency
and recency of oral contraceptive (OC) use (based on data in Table I)
Relative risk estimates (95% CI)ab
Cervical
Breast Ovarian Cervical intraepithelial
cancer cancer cancer neoplasia
Time sincefirst
OC use (years)
<10 0.73 0.55 1.76 0.67
(0.49-1.09) (0.35-0.90) (0.86-3.58) (0.41-1.10)
>10 1.45 0.84 1.22 1.02
(1.01-2.08) (0.50-1.39) (0.59-2.54) (0.54-1.91)
Time since last
OC use (years)
<5 0.75 0.58 2.51 0.79
(0.44-1.27) (0.30-1.11) (1.00-6.33) (0.46-1.38)
>5 1.38 0.75 1.34 0.83
(1.00-1.92) (0.48-1.15) (0.69-2.61) (0.46-1.47)
aMantel-Haenszel estimates adjusted for age in decades; bReference category: never OC users.ORAL CONTRACEPTIVES, BREAST AND GENITAL CANCER 315
Table V Relative risk estimates of breast and female
genital tract neoplasms in relation to ever use of oral
contraceptives (OC), age and parity
Relative risk estimatesab
Cervical
Breast Ovarian Cervical intraepithelial
Covariate cancer cancer cancer neoplasia
Age (years)
<40 0.87 0.86 1.42 0.68
(129)' (65) (62) (115)
40-49 1.23 0.59 1.40 0.92
(311) (141) (72) (66)
50-59 0.91 0.96 2.07 2.10
(336) (200) (91) (21)
Parityab
0 1.16 0.83 1.82 0.75
(149) (115) (19) (36)
>1 1.00 0.57 1.30 0.71
(627) (291) (206) (166)
aMantel-Haenszel estimates adjusted for age in decades.
bReference category: never OC users. cThe number of
cases in each group is given in parentheses.
among ever users was consistent across strata of
age or parity (Table V).
Cancer ofthe endometrium
Combination oral contraceptives had been used by
only seven (4.1%) endometrial cancer cases. This,
of course, should be considered in the light of the
relatively older age of women with the cancer of
the corpus uteri, over 70% of the cases being aged
50 to 59. The estimated relative risk for ever use,
though considerably below unity (age-adjusted
RR =0.50), did not reach formal statistical
significance (Table II). The low number of OC
users among cases precluded any further analysis of
sub-groups.
Invasive cancer ofthe cervix uteri
There were 43 (19.1%) women with invasive
cervical cancer and 32 (14.2%) age-matched
controls who had at one time used combination
oral contraceptives. The age-adjusted relative risk
was 1.49 (95% CI=0.88-2.55) and increased to
1.74 when allowance was made for several potential
confounding factors (including rather detailed
information on sexual habits) by means of multiple
logistic regression (Table II). The risk estimate was
higher (RR =2.94) for >2 year duration of use,
and this test for linear trend was statistically
significant (Table III). However, the relative risks
were slightly greater for women who had first used
oral contraceptives less than ten years prior to
diagnosis or interview or last used them less than
five years before. The interactions with reference to
latency and recency of use, however, were far from
significant, and may easily be due to chance.
No important difference was evident in various
strata of age or parity considered (Table V).
Cervical intra-epithelial neoplasia
Ever use or oral contraceptives was reported by 71
(35.1%) cases of cervical intra-epithelial neoplasia
and 82 (40.6%) age matched controls, giving a
relative risk estimate of 0.77 (95% CI=0.50-1.18).
Adjustment for all identified potential confounding
factors did not materially change this estimate
(multivariate RR=0.69, Table II).
The point estimates remained slightly (and not
significantly) below unity when various levels of
duration, latency or recency were considered
(Tables III and IV), and (for ever OC use) in most
strata of age or parity analysed (Table V).
Discussion
In the present study, women who used combination
oral contraceptives appeared to experience a
substantially reduced risk of epithelial ovarian
cancer or cancer of the corpus uteri, whereas no
association emerged between oral contraceptives
and cancer of the breast. The risk of invasive.
cervical cancer was elevated in women who had
used oral contraceptives for longer than two years.
However, there was little consistent relation with
latency or recency of use for invasive cervical
cancer, and no overall association with pre-invasive
conditions.
The pattern of use of oral contraceptives is
clearly different in the present northern Italian
population compared with other studies, mostly
based on North American data. On a whole, only
about 14% of the women aged under 60 in the two
inpatient control groups had at any time used oral
contraceptives versus 50 per cent or more in
American series of comparable age (Centers for
Disease Control Cancer and Steroid Hormone
Study, 1983a,b,c; Rosenberg et al., 1984). The
larger proportion of ever users (-40%) anmong the
present outpatient comparison group for cervical
intraepithelial neoplasia is obviously due to the
younger age of these subjects (median age=37
years) and, possibly, to their selection criteria, since
more educated and higher social class women in
Italy tend to use oral contraceptives more
commonly an'd, as expected, preferentially attend
screening clinics (La Vecchia et al., 1984b). These316 C. LA VECCHIA et al.
subjects, in any case, were compared with cases of
pre-invasive conditions identified in the same
outpatients screening clinics. Furthermore, average
duration of use was considerably shorter in the
present Italian population, since only about 5% of
the inpatient comparison group and 16% of
outpatient controls had used combination oral
contraceptives for more than two years.
Thus, the absence of association between oral
contraceptive use and the risk of breast cancer
might be attributed to the low power of the present
study. It is therefore of interest, within the overall
design of the study, that the negative associations
with ovarian (Newhouse et al., 1977; Rosenberg et
al., 1982; Centers for Disease Control Cancer and
Steroid Hormone Study, 1985b) or endometrial
(Kaufman et al., 1980; Centers for Disease Control
Cancer and Steroid Hormone Study, 1983c) cancers
previously reported in several studies conducted in
different populations were consistently confirmed in
the present data.
Moreover, in American or British data as well
there is little consistent evidence of a positive
association between oral contraceptive use and
breast cancer risk, though various studies reported
elevated relative risks in specific subgroups (Fasal
& Paffenbarger, 1975; Brinton et al., 1982; Janerich
et al., 1983).
With regard to cervical neoplasia, the present
results can hardly be considered at variance with
previous general evidence. In fact, the pooled
relative risk for cervical abnormalities (mostly
displasia or in situ carcinoma) from seven case-
control studies or prospective investigations
analysed as case-controls conducted in North
America, Britain and Czechoslovakia (Thomas,
1972; Worth and Boyes, 1972; Boyce et al., 1977;
Ory et al., 1977; Harris et al., 1980; Vonka et al.,
1984; WHO Collaborative Study on Neoplasia and
Steroid Contraceptives, 1985) and based on a total
of over 20,000 subjects was 1.1 (Franceschi et al.,
1986) thus indicating no or a very limited material
overall elevation of risk in oral contraceptives users.
It may also of interest to note that, in the present
study, women who had ever used oral contracep-
tives did not have a larger number of sexual
partners than those using other or no contraceptive
method, but they did report more frequent
screening 'Pap' smears, which have been reported
to reduce risk of cervical cancer (La Vecchia et al.,
1984b). Although the overall risk estimate for
invasive cervical cancer among ever OC users was
only slightly and insignificantly elevated, and the
relative risk for intraepithelial neoplasia was below
unity, a significantly elevated invasive cancer risk
was evident among women who had used oral
contraceptives for over two years. This evidence,
however, based on limited absolute numbers, is
consistent with recent data from various other
countries (WHO Collaborative Study of Neoplasia
and Steroid Contraceptives, 1985; Brinton et al.,
1985).
In conclusion, the results of this study provide
further reassurance on the relation between oral
contraceptive use and cancers of the breast, ovary
and endometrium, since in a population with
broadly different general characteristics and contra-
ceptive use patterns they confirm the negative
association with ovarian or endometrial cancer risk
previously reported mostly in American data.
Furthermore, they indicate that the past or current
pattern of oral contraceptive use in Italy is unlikely
materially to affect the risk of breast cancer.
Although the present data are clearly of little help
in evaluating long-term use of oral contraceptives,
or their potential effects on cancer risk after long
latent intervals, the elevated invasive cervical cancer
risk among long term users is clearly worrying and
warrants further investigation on large sets of data.
The present work was conducted within the framework of
the CNR (Italian National Research Council) applied
projects 'Preventive and Rehabilitative Medicine'
(Contracts No. 84.02233.56 and 84.02299.56) and
'Oncology' (Contract No. 85.02209.44), with a grant in
aid by Wyeth and Schering Italia SpA, and with the
contribution of the Italian Association for Cancer
Research, Milan, Italy.
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